If you're taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, these could be early signs of gastroparesis—a condition where stomach emptying slows dangerously. The medical community has long emphasized the importance of recognizing adverse drug reactions early to prevent serious complications. This page outlines the clinical red flags that California patients and providers should watch for.
Building on this foundation, we now examine the specific case of Ozempic (semaglutide), a glucagon-like peptide-1 (GLP-1) receptor agonist approved for glycemic control in type 2 diabetes. Its pharmacological action slows gastric emptying, a mechanism that can, in susceptible individuals, progress to gastroparesis—a condition characterized by delayed gastric emptying without mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, and abdominal pain. Clinical diagnosis of gastroparesis typically involves gastric emptying scintigraphy showing delayed emptying after a standardized meal, along with symptom assessment. The link between Ozempic and gastroparesis is mechanistically plausible: GLP-1 receptor agonists delay gastric motility, and prolonged use may exacerbate or unmask underlying gastroparesis in some patients. Evidence from clinical trials documents a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo. In pooled placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of nausea, vomiting, and diarrhea reports occurred during dose escalation. Discontinuation due to gastrointestinal adverse reactions was higher with Ozempic (3.1% for 0.5 mg, 3.8% for 1 mg) versus placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with frequencies below 5% included dyspepsia (1.9% placebo, 3.5% Ozempic 0.5 mg, 2.7% Ozempic 1 mg), eructation, flatulence, gastroesophageal reflux disease, and gastritis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). These data indicate a dose-dependent increase in gastrointestinal side effects, though gastroparesis itself is not explicitly listed as a reported adverse reaction in the label.
The adequacy of warnings regarding Ozempic and gastroparesis is a key risk anchor. The prescribing information includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically warn about gastroparesis. This omission may affect the legal standard for failure-to-warn claims in California, where manufacturers must provide adequate warnings of known or reasonably knowable risks. Given the mechanistic link and reported gastrointestinal effects, plaintiffs may argue that the risk of gastroparesis should have been more explicitly communicated. For affected patients in California, settlement-related considerations depend on the statute of limitations. California law generally requires personal injury claims to be filed within two years of the date of injury or discovery of the injury. For Ozempic-related gastroparesis, the timeline between exposure and documented harm is critical. Symptoms may develop gradually during dose escalation or after prolonged use, making the date of discovery potentially later than the initial prescription. Patients should document when they first experienced symptoms consistent with gastroparesis (e.g., persistent nausea, vomiting, abdominal pain) and when a formal diagnosis was made. The statute of limitations may begin at the point the patient knew or should have known that Ozempic caused their condition. Legal counsel can assess whether the claim falls within the two-year window or if exceptions apply, such as delayed discovery due to latent injury.
Risk anchors also include the adequacy of warnings. The label does not list gastroparesis as a specific adverse reaction, but the high rate of gastrointestinal adverse reactions and the known effect on gastric emptying may support a claim that the manufacturer failed to warn about this serious complication. Settlement negotiations may consider the strength of the causal evidence, the severity of the patient's condition, and the timing of the injury relative to the statute of limitations. In summary, patients in California who developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery of the injury. The mechanistic link between Ozempic and delayed gastric emptying, combined with clinical trial data showing elevated gastrointestinal adverse reactions, provides a basis for potential claims. However, the lack of explicit gastroparesis warnings in the label may be a point of contention. Affected individuals should consult with a legal professional to evaluate their specific circumstances and ensure timely filing. References (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166)
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
California law generally requires personal injury claims to be filed within two years from the date of injury or discovery of the injury. For Ozempic-related gastroparesis, the clock may start when the patient knew or should have known that Ozempic caused their condition. It is crucial to document symptom onset and diagnosis to determine the exact deadline.
The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions and hypersensitivity reactions such as anaphylaxis and angioedema (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166), but does not specifically warn about gastroparesis. This omission may be relevant in failure-to-warn claims.
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.